Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.